Medytox signs an MOU to build a 'Toxin' factory in Dubai
This article is translated by AI company Flitto and Alhpabiz neural machine translation technology
김지선
stockmk2020@alphabiz.co.kr | 2023-01-17 10:44:11
[Alphabiz=(Chicago) Reporter Kim Jisun] Biopharmaceutical company Medytox (CEO Chung Hyun-ho) signed a memorandum of understanding (MOU) on the construction of a toxin finished product plant with Marwan Abdulaziz Janahi, owned by Dubai's state-run Tecom Group at the Korea-UAE Business Forum held at the Rixos Marina Hotel in Abu Dhabi, the United Arab Emirates (UAE) on the 16th (local time).
With the signing of the MOU, Medytox will build a production facility based on the liquid toxin drug "MT10109L" in Dubai, and plans to target the global Muslim market and the Middle Eastern and European markets through HALAL certification.
Meanwhile, when Medytox builds a toxin finished product production facility in Dubai, it will be the first Korean company to have a toxin production facility overseas. With this MOU as an opportunity, Medytox has begun detailed consultations on future implementation measures and plans to sign the contract once discussions are completed
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1NH Investment & Securities Cuts NAVER Target Price to KRW 320,000, Maintains ‘Buy’ on AI Growth Outlook
- 2Korean Air and LCC Affiliates Enter Emergency Management as Fuel Costs Surge Amid Middle East Conflict
- 3Amazon Web Services to Invest KRW 7 Trillion More in Korea by 2031, Expanding AI Infrastructure
- 4Lotte Group to Launch KRW 50 Trillion Real Estate Development Push to Tackle Liquidity Pressures
- 5China Vanke Posts Record Loss as Property Slump Deepens Financial Strain
- 6Daesang Executive Arrested in KRW 10 Trillion Sweetener Price-Fixing Probe; CEOs Avoid Detention